Rejection under alpha interferon therapy in liver transplant recipients

Area of Science:

• Hepatology
• Transplant Immunology
• Virology

Background:

• Interferon alpha (IFN) is a primary treatment for recurrent hepatitis C (HCV) in liver transplant (LT) recipients.
• A significant adverse effect of IFN is acute and chronic graft rejection.
• Understanding rejection incidence and risk factors is crucial for managing LT patients on IFN therapy.

Purpose of the Study:

• To review the incidence and risk factors of rejection in LT recipients treated with IFN-based therapy.
• To evaluate the outcomes of LT patients who experienced rejection during IFN therapy.
• To identify predictors of rejection and assess treatment success rates.

Main Methods:

• Retrospective review of 70 LT recipients treated with IFN-based therapy between September 1990 and December 2004.
• Analysis of patient data including time to antiviral treatment post-LT, rejection incidence, and Banff classification.
• Statistical analysis to identify risk factors associated with rejection, including prior rejection history and type of IFN used.

Main Results:

• Twenty-one percent of patients developed acute rejection during IFN-based therapy.
• Previous acute rejection and use of pegylated-IFN were significantly associated with higher rejection rates (p=0.04 and p=0.02, respectively).
• Rejection was successfully treated in 87% of patients, with no observed chronic rejection or graft loss.

Conclusions:

• Acute rejection is a notable complication of IFN-based therapy in LT recipients.
• Early diagnosis via protocol biopsies and prompt treatment are key to successful management.
• IFN therapy can be safely used in LT recipients with careful monitoring for rejection.